DOCSLIB.ORG

Vaccines and Related Biological Products Advisory Committee (VRBPAC) Meeting

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Vaccines and Related Biological Products Advisory Committee (VRBPAC) Meeting FOOD AND DRUG ADMINISTRATION (FDA) Center for Biologics Evaluation and Research (CBER) 164th Vaccines and Related Biological Products Advisory Committee (VRBPAC) Meeting OPEN PUBLIC MEETING Web-Conference Silver Spring, Maryland 20993 February 26, 2021 This transcript appears as received from the commercial transcribing service after inclusion of minor corrections to typographical and factual errors recommended by the DFO. 2 ATTENDEES COMMITTEE MEMBERS Paula Annunziato, M.D. Merck Archana Chatterjee, M.D., Ph.D. Rosalind Franklin University National Center for Immunizations and CAPT Amanda Cohn, M.D. Respiratory Diseases Centers for Disease Control and Prevention Hayley Gans, M.D. Stanford University Medical Center Michael Kurilla, M.D., Ph.D. National Institutes of Health H. Cody Meissner, M.D. Tufts University School of Medicine Paul Offit, M.D. The Children’s Hospital of Philadelphia Steven A. Pergam, M.D., M.P.H., FIDSA Seattle Cancer Care Alliance TEMPORARY VOTING MEMBERS Arnold Monto, M.D. (Acting Chair) University of Michigan A. Oveta Fuller, Ph.D. University of Michigan James Hildreth, Sr., Ph.D., M.D. Meharry Medical College U.S. Department of Health and Human David Kim, M.D., M.A. Services Jeannette Lee, Ph.D. University of Arkansas for Medical Sciences Ofer Levy, M.D., Ph.D. Massachusetts Institute of Technology Wayne A. Marasco, M.D., Ph.D. Harvard Medical School Pamela McInnes, D.D.S., M.Sc. National Institutes of Health Patrick Moore, M.D., M.P.H. University of Pittsburgh Cancer Institute Stanley Perlman, M.D., Ph.D. University of Iowa Jay Portnoy, M.D. Children's Mercy Hospital www.transcriptionetc.com 3 Eric Rubin, M.D., Ph.D. Brigham and Women’s Hospital Mark Sawyer, M.D., F.A.A.P. Rady Children’s Hospital San Diego Melinda Wharton, M.D, M.P.H. Centers for Disease Control and Prevention GUEST SPEAKERS Adam MacNeil, Ph.D., M.P.H. Centers for Disease Control and Prevention Tom Shimabukuro, M.D., M.P.H., M.B.A. Centers for Disease Control and Prevention SPONSOR Janssen Pharmaceuticals Companies of Macaya Douoguih, M.D., M.P.H. Johnson & Johnson Gregory A. Poland, M.D., F.R.C.P. Mayo Clinic Janssen Pharmaceuticals Companies of Hanneke Schuitemaker, Ph.D. Johnson & Johnson Janssen Pharmaceuticals Companies of Johan Van Hoof, M.D. Johnson & Johnson FDA SPEAKERS/PARTICIPANTS Maria Allende, M.D. Center for Biologics Evaluation and Research Steven Anderson, Ph.D., M.P.P. Center for Biologics Evaluation and Research Doran Fink, Ph.D. Food and Drug Administration Marion Gruber, Ph.D. Food and Drug Administration Yosefa Hefter, M.D. Center for Biologics Evaluation and Research Philip Krause, M.D. Food and Drug Administration Peter W. Marks, M.D., Ph.D. Food and Drug Administration CDR Valerie Marshall, M.P.H., P.M.P. Food and Drug Administration Jerry Weir, Ph.D. Food and Drug Administration Celia M. Witten, Ph.D., M.D. Food and Drug Administration www.transcriptionetc.com 4 Rachel Zang, M.D. Center for Biologics Evaluation and Research FDA ADMINISTRATIVE STAFF Prabhakara Atreya, Ph.D. Food and Drug Administration Kathleen Hayes, M.P.H. Food and Drug Administration Monique Hill, M.H.A. Food and Drug Administration Michael Kawczynski Food and Drug Administration www.transcriptionetc.com 5 TABLE OF CONTENTS OPENING REMARKS: CALL TO ORDER AND WELCOME................ 6 ADMINISTRATIVE ANNOUNCEMENTS, ROLL CALL, INTRODUCTION OF COMMITTEE, CONFLICT OF INTEREST STATEMENT .................................................................................... 8 FDA PRESENTATION ON EMERGENCY USE AUTHORIZATION ... 26 EPIDEMIOLOGY OF COVID-19 VARIANTS .................................... 39 POSTMARKETING SURVEILLANCE FROM CURRENTLY AUTHORIZED COVID-19 VACCINES ............................................. 70 SPONSOR PRESENTATION: EMERGENCY USE AUTHORIZATION APPLICATION FOR COVID-19 VACCINE ....................................... 95 ADDITIONAL Q & A FOR SPONSOR PRESENTERS .......................143 OPEN PUBLIC HEARING ...............................................................163 FDA PRESENTATION AND VOTING QUESTIONS .........................217 COMMITTEE DISCUSSION AND VOTING .....................................266 www.transcriptionetc.com 6 1 OPENING REMARKS: CALL TO ORDER AND WELCOME 2 3 MR. MICHAEL KAWCZYNSKI: Good morning and 4 welcome to the 164th meeting of Vaccines and Related 5 Biological Products Advisory Committee meeting. I'm 6 Mike Kawczynski, project manager with FDA, and I'll be 7 today's meeting facilitator. This is a live virtual 8 public meeting that is being broadcast in its entirety 9 though C-SPAN, YorkCast, Facebook Live, YouTube, 10 Twitter, and various other methods. 11 Today’s event is also being recorded and will 12 be posted on the FDA’s VRBPAC webpage along with all 13 relevant meeting materials. Throughout today’s meeting, 14 I will be reminding our speakers and presenters 15 committee members and sponsors as to when it's closer 16 to their allotted time and assisting them when needed. 17 Just a reminder to everyone that once called 18 upon, please manage your mute and activate your 19 webcams. Note to all members and participants, we are 20 aware of the adverse weather conditions some of you -- 21 and are having to take precautions, and, if we www.transcriptionetc.com 7 1 encounter any issues, we will take it on a scheduled 2 break. At this time, I’d like to now introduce Dr. 3 Arnold Monto, the acting chair, who will now provide 4 opening remarks. 5 Dr. Monto, please, activate your webcam and 6 take it away. 7 DR. ARNOLD MONTO: Good morning. I'd like to 8 open this meeting, the 164th meeting of the Vaccines 9 and Related Biological Products Advisory Committee and 10 to specifically tell us -- state the reason for our 11 meeting, and this is to provide and discuss Emergency 12 Use Authorization of the Janssen Biotech COVID-19 13 vaccine for active immunization to prevent COVID-19 14 caused by SARS-CoV-2 in individuals 18 years of age and 15 older. 16 I would also like to welcome to the meeting 17 our voting members, our standing members, the other 18 speakers, those representing the sponsor Janssen as 19 well as the public. Your participation is very 20 important because you will see an open meeting 21 discussing scientific findings in action. www.transcriptionetc.com 8 1 And now I'd like to turn over to the 2 designated federal officer for this meeting, Prabha 3 Atreya. Prabha. 4 5 ADMINISTRATIVE ANNOUNCEMENTS, ROLL CALL, INTRODUCTION 6 OF COMMITTEE, CONFLICT OF INTEREST STATEMENT 7 8 DR. PRABHAKARA ATRAYA: Thank you, Dr. Monto. 9 Good morning, everyone. This is Prabha Atraya, and it 10 is my great honor to serve as the designated federal 11 officer for today's 164th Vaccines and Related 12 Biological Products Advisory Committee meeting. 13 On behalf of the FDA, the Center for Biologics 14 Evaluation and Research, and the Committee, I would 15 like to welcome everyone to this virtual meeting. The 16 topic of the meeting, as Dr. Monto mentioned, is the 17 Emergency Use Authorization of Janssen Biotech's COVID- 18 19 vaccine for the active immunization to prevent 19 COVID-19 caused by SARS-CoV-2 in individuals 18 years 20 and older. Today’s meeting and the topic were 21 announced in the federal register notice that was www.transcriptionetc.com 9 1 published on February 11, 2021. 2 I would like to introduce and acknowledge the 3 excellent contributions of the staff in my division and 4 the great support team we have in preparing for this 5 meeting. 6 Ms. Kathleen Hayes is my backup and co-DFO 7 providing excellent support in all aspects of preparing 8 for and conducting this meeting. The other staff are 9 Ms. Monique Hill, Dr. Jeannette Devine, and Christina 10 Vert, who provided excellent administrative support. 11 Thank you, DSAC team, for your support. 12 I would like to express CBER's sincere 13 appreciation to Mike Kawczynski for facilitating the 14 meeting for today and also a big shout out to many FDA 15 staff working hard behind the scenes trying to ensure 16 that today's virtual meeting will also be a successful 17 one like the previous three VRBPAC meetings on the 18 COVID topic. 19 Please direct any press or media questions for 20 today’s meeting to the FDA’s Office of Media Affairs or 21 FDAOMA -- one word -- @fda.hhs.gov. The www.transcriptionetc.com 10 1 transcriptionist for today’s meeting is Ms. Linda 2 Giles. 3 We will begin today’s meeting by taking a 4 formal role call for the Committee members and 5 temporary members. When it is your turn, please turn 6 on your camera, unmute your phone, and then state your 7 first and last name, and, when finished, you can turn 8 your camera off so we can proceed to the next person. 9 Please see the member roster slide in which we will 10 begin with the chair. Dr. Arnold Monto, can we start 11 with you, please? 12 DR. ARNOLD MONTO: Good morning, again, and 13 welcome to all. 14 DR. PRABHAKARA ATRAYA: I think, Dr. Monto, 15 your volume is a little bit low. If you can improve 16 it, that would be great. Thank you. Dr. Amanda Cohn. 17 DR. AMANDA COHN: Good morning. Dr. Amanda 18 Cohn, Chief Medical Officer at the National Center for 19 Immunization and Respiratory Diseases. 20 DR. PRABHAKARA ATRAYA: Thank you. Dr. 21 Chatterjee. www.transcriptionetc.com 11 1 DR. ARCHANA CHATTERJEE: Good morning. My 2 name is Archana Chatterjee. I am the dean of Chicago 3 Medical School and Vice President for Medical Affairs 4 as Rosalind Franklin University of Medicine and 5 Science. I'm a pediatric infectious diseases 6 specialist with a background in research in vaccines. 7 Thank you. 8 DR. PRABHAKARA ATRAYA: Great. Dr. Cody 9 Meissner. 10 DR. CODY MEISSNER: Good morning.
Load more

Recommended publications
  • Breast Implants: Choices Women Thought They Made
    NYLS Journal of Human Rights Volume 11 Issue 1 Article 5 Fall 1993 BREAST IMPLANTS: CHOICES WOMEN THOUGHT THEY MADE Zoe Panarites Follow this and additional works at: https://digitalcommons.nyls.edu/journal_of_human_rights Part of the Law Commons Recommended Citation Panarites, Zoe (1993) "BREAST IMPLANTS: CHOICES WOMEN THOUGHT THEY MADE," NYLS Journal of Human Rights: Vol. 11 : Iss. 1 , Article 5. Available at: https://digitalcommons.nyls.edu/journal_of_human_rights/vol11/iss1/5 This Notes and Comments is brought to you for free and open access by DigitalCommons@NYLS. It has been accepted for inclusion in NYLS Journal of Human Rights by an authorized editor of DigitalCommons@NYLS. BREAST IMPLANTS: CHOICES WOMEN THOUGHT THEY MADE Nearly two million women- received breast implants between 1962 and 1991: eighty percent for cosmetic purposes, and twenty percent for reconstructive surgery following mastectomies. 1 From their inauspicious beginnings as a tool for Japanese prostitutes during World War II to enlarge their breasts for American servicemen, 2 implants have now been deemed crucial to post-mastectomy recipients3 and other women seeking self-improvement." Implants are © Copyright 1993 by the New York Law School Journalof Human Rights. 'John R. Easter ct al., Medical "State of the Art"for the Breast Implant Litigation, in BREAST IMPLANT Lrrio. 1, 12 (Law Journal Seminars-Press 1992). This Note will focus primarily on silicone-filled implants. Food and Drug Administration ("FDA") estimates released in 1988 indicate that only 15% of implant surgeries were for reconstructive purposes, while 85% were for cosmetic purposes. Teich v. FDA, 751 F. Supp. 243, 245-46 (D.D.C.
    [Show full text]
  • Spring/Summer 2019
    34 We are dedicated to improving the health and How Can We Cut the Cost of Medical Care? safety of adults and children by using research to develop Everyone agrees that health insurance is too Our own research on cancer drugs found that expensive and prescription drugs cost much too many that were recently approved based on their more effective treatments and much – some cost more than patients’ annual success at shrinking tumors provided zero benefit income! The amount Americans spend on to the average patient in terms of living longer or policies. The Cancer prescription drugs has nearly doubled since the having a better quality of life. Since cancer drugs Prevention and Treatment 1990s, and today the most expensive drugs cost so often cause nausea, vomiting, exhaustion, and $500,000 or more per year. other debilitating side effects, it is unconscionable Fund is our major program. that these drugs are being approved without clear What’s the solution? evidence that they work – or which patients have at least some chance of benefitting even if most This article isn’t about Medicare for All, Medicaid don’t. for All, or other major legislation, all of which face enormous political and corporate opposition. Instead, this article focuses on the issues that would be easier to fix in the near term. How to Spend Less on Drugs and Medical Tests Too many patients are being priced out of the Our Cancer Prevention and medical treatment that they need – or think they Treatment Fund helps adults need. As prices have risen, companies have broken one record after another, so that it seems there is and children reduce their risk no limit on what they will charge.
    [Show full text]
  • Fall 2018/Winter 2019
    ISSUE ISSUE 2433 TheTheVoice Voice FALL/WINTER 2018 FOR PREVENTION, TREATMENT, AND POLICY SPRING/SUMMER 2014 FOR PREVENTION, TREATMENT, AND POLICY National WHAT’S INSIDE We’re in the Headlines…2 Center Brain Stimulation as a Treatment for Depression?...3 What are the Implant Files?...4 for Health Is the Affordable Care Act Still at Risk?....4 What is Breast Implant Illness?...5 Research Honoring Foremothers….6 Dietary Supplements...7 We are dedicated to improving the health and safety of adults and children by Can Sleeping Pills Cause Cancer? Can Avoiding using research to develop more Them Improve Your Health? effective treatments and policies. The Cancer Americans spend more than $41 billion each year on prescription sleeping pills, and that doesn’t Prevention and Treatment count the popular over-the-counter sleep aids such Fund is our major program. as Tylenol PM and Benadryl. If you are one of the many Americans that needs help sleeping, you’ll want to know about a study showing that people who take these drugs are significantly more likely to be diagnosed with cancer or to die within the next The Cancer two and a half years than people who don’t take Even before this study, there were at least 18 other them. Published in the prestigious British Medical studies showing an increased risk of death for Prevention Journal, author Dr. Daniel Kripke estimates that people taking sleeping pills, and several also and Treatment sleep medications could be causing more than showed an increased risk of cancer. However, this Fund 300,000-500,000 deaths every year.
    [Show full text]
  • Implications for Patients and Health Policy Conference Agenda
    What Evidence is Essential for New Medical Products? Implications for Patients and Health Policy June 13, 2014 AAAS Headquarters Washington, DC Conference Agenda 8:00 am Registration 8:30 am Welcome Remarks: Mark S. Frankel American Association for the Advancement of Science 8:40 am Keynote Addresses Introductions: Diana Zuckerman National Center for Health Research 8:45 am Remarks: Congresswoman Rosa L. DeLauro (D-CT) 9:05 am Remarks: Margaret R. Hamburg (via live video) Food & Drug Administration 9:15 am Panel I. Evidence-Based Policy: Opportunities and Challenges Moderator: Susan F. Wood George Washington University Speakers: Aaron S. Kesselheim Brigham and Women’s Hospital/Harvard Medical School Robert Yarchoan National Cancer Institute Gregory D. Curfman New England Journal of Medicine Rita F. Redberg JAMA Internal Medicine 10:45 am Panel II. Speed vs. Safety: Implications for Public Health of Changing Standards for Getting Products to Market Moderator: Kim Witczak Patient Safety Advocate Speakers: Bernard Lo Greenwall Foundation Lisa M. Schwartz & Steven Woloshin Dartmouth Medical School Michael Rosenblatt Merck 12:00 pm Lunch 1:00 pm Panel III. Biomarkers, Surrogate Endpoints and Other Shortcuts that May or May Not Predict Health Outcomes Moderator: Thomas J. Moore Institute for Safe Medication Practices Speakers: Jerry Avorn Brigham and Women’s Hospital/Harvard Medical School Joseph S. Ross Yale School of Medicine Diana Zuckerman National Center for Health Research Ann de Velasco WomenHeart of Miami 2:30 pm Panel IV. Post-Market Surveillance and Comparative Effectiveness Research Moderator: Tianjing Li Johns Hopkins University Speakers: Robert Ball Food & Drug Administration Sebastian Schneeweiss Brigham and Women’s Hospital/Harvard Medical School Patrick Ryan Janssen Research and Development 3:45 pm Break 4:00 pm Panel V.
    [Show full text]
  • Long Term Effects of Dab Pens
    Long Term Effects Of Dab Pens Heavy-handed Corrie louts indestructibly. Is Woodrow culicid or semiparasitic after cotemporaneous mimicsTheo automobiles very vaingloriously so sycophantically? and spryly? Is Cole always theism and geochemical when cooperated some In design and long term This field is created when you smoked, also find the aerosol is the pipe and general categories: an fda approval that a breakdown in. But, the truth no the felt is that individuals would not recover the symptoms of withdrawal if there now nothing to disperse from. What boss a cannabis dab pen Leafly. Is Vaping Bad play You Vaping vs Smoking Side Effects and. Weed vapes What you need to make about marijuana CNET. Learn learn the research. Like many vaping products, different batteries provide varying functions and are compatible with disease other products. Another person realized he is dabbing temperatures needed a long run low and effects that cbd and dependence: which contains no. Publications and Reports of the Surgeon General. Early reactions to dab pens. Dna damage to list of? This includes the script as async. Are and aware, has there enough people, companies and bloggers who override their entire days unraveling these lies and exposing the truth lend them? Very friendly but helpful ready with vast product knowledge. Our comments here to not intended it a diatribe against vaping or the legalization of cannabis. It whereas Black Note. The Mighty is no portable powerhouse. Diana zuckerman and. You could probably do consent better. Medical staff revise the depth in Miami, where she as been airlifted, struggled to keep anyone alive.
    [Show full text]
  • Strategies for Improving Influenza Immunization Rates Among Hard-To-Reach Populations
    Journal of Urban Health: Bulletin of the New York Academy of Medicine, Vol. 84, No. 4 doi:10.1007/s11524-007-9197-z * 2007 The New York Academy of Medicine For permissions, please e-mail: [email protected] Advance Access publication Strategies for Improving Influenza Immunization Rates among Hard-to-Reach Populations David Vlahov, Micaela H. Coady, Danielle C. Ompad, and Sandro Galea ABSTRACT Whereas considerable attention has been devoted to achieving high levels of influenza immunization, the importance of this issue is magnified by concern over pandemic influenza. Most recommendations for vaccine administration address high risk groups such as the elderly and those with chronic diseases, but coverage for hard- to-reach (HTR) populations has had less attention. HTR populations include minorities but also include other primarily urban groups such as undocumented immigrants, substance users, the homeless, and homebound elderly. Obstacles to the provision of immunization to HTR populations are present at the patient, provider, and structural levels. Strategies at the individual level for increasing immunization coverage include community-based educational campaigns to improve attitudes and increase motivation for receiving vaccine; at the provider level, education of providers to encourage immunizations, improving patient–provider interactions, broadening the provider base to include additional nurses and pharmacists, and adoption of standing orders for immunization administration; and at the structural level, promoting
    [Show full text]
  • OPTIONS X Programme
    Options X for the Control of Influenza | WELCOME MESSAGES BREAKTHROUGH INFLUENZA VACCINES TAKE LARGE DOSES OF INNOVATION Protecting people from the ever-changing threat of influenza takes unwavering commitment. That’s why we’re dedicated to developing advanced technologies and vaccines that can fight influenza as it evolves. We’re with you. ON THE FRONT LINETM BREAKTHROUGH INFLUENZA VACCINES TAKE LARGE DOSES OF INNOVATION CONTENT OPTIONS X SUPPORTERS ------------------- 4 OPTIONS X EXHIBITORS & COMMITTEES ------------------- 5 AWARD INFORMATION ------------------- 6 WELCOME MESSAGES ------------------- 7 SCHEDULE AT A GLANCE ------------------- 10 CONFERENCE INFORMATION ------------------- 11 SOCIAL PROGRAMME ------------------- 14 ABOUT SINGAPORE ------------------- 15 SUNTEC FLOORPLAN ------------------- 16 SCIENTIFIC COMMUNICATIONS ------------------- 17 PROGRAMME ------------------- 19 SPEAKERS ------------------- 31 SPONSORED SYMPOSIA ------------------- 39 ORAL PRESENTATION LISTINGS ------------------- 42 POSTER PRESENTATION LISTINGS ------------------- 51 ABSTRACTS POSTER DISPLAY LISTINGS ------------------- 54 SPONSOR AND EXHIBITOR LISTINGS ------------------- 80 EXHIBITION FLOORPLAN ------------------- 83 Protecting people from the ever-changing threat of NOTE ------------------- 84 influenza takes unwavering commitment. That’s why we’re dedicated to developing advanced technologies and vaccines that can fight influenza as it evolves. We’re with you. ON THE FRONT LINETM Options X for the Control of Influenza | OPTIONS X SUPPORTERS
    [Show full text]
  • INSTITUTION Congress of the US, Washington, DC. House Committee
    DOCUMENT RESUME ED 303 136 IR 013 589 TITLE Commercialization of Children's Television. Hearings on H.R. 3288, H.R. 3966, and H.R. 4125: Bills To Require the FCC To Reinstate Restrictions on Advertising during Children's Television, To Enforce the Obligation of Broadcasters To Meet the Educational Needs of the Child Audience, and for Other Purposes, before the Subcommittee on Telecommunications and Finance of the Committee on Energy and Commerce, House of Representatives, One Hundredth Congress (September 15, 1987 and March 17, 1988). INSTITUTION Congress of the U.S., Washington, DC. House Committee on Energy and Commerce. PUB DATE 88 NOTE 354p.; Serial No. 100-93. Portions contain small print. AVAILABLE FROM Superintendent of Documents, Congressional Sales Office, U.S. Government Printing Office, Washington, DC 20402. PUB TYPE Legal/Legislative/Regulatory Materials (090) -- Viewpoints (120) -- Reports - Evaluative/Feasibility (142) EDRS PRICE MFO1 /PC15 Plus Postage. DESCRIPTORS *Advertising; *Childrens Television; *Commercial Television; *Federal Legislation; Hearings; Policy Formation; *Programing (Broadcast); *Television Commercials; Television Research; Toys IDENTIFIERS Congress 100th; Federal Communications Commission ABSTRACT This report provides transcripts of two hearings held 6 months apart before a subcommittee of the House of Representatives on three bills which would require the Federal Communications Commission to reinstate restrictions on advertising on children's television programs. The texts of the bills under consideration, H.R. 3288, H.R. 3966, and H.R. 4125 are also provided. Testimony and statements were presented by:(1) Representative Terry L. Bruce of Illinois; (2) Peggy Charren, Action for Children's Television; (3) Robert Chase, National Education Association; (4) John Claster, Claster Television; (5) William Dietz, Tufts New England Medical Center; (6) Wallace Jorgenson, National Association of Broadcasters; (7) Dale L.
    [Show full text]
  • Introduction Fact Checking
    Innovative Health Solutions’ Response to NPR Story: Questions Raised About Study of Device to Ease Opioid Withdrawal Introduction Jake Harper’s NPR story, Questions Raised About Study of Device to Ease Opioid Withdrawal, presented a biased and misleading view of the NSS-2 BRIDGE device. To address his story’s factual inaccuracies, this document provides a comparison to many of Harper’s claims with facts backed by the IHS team and its research. Fact Checking Inaccuracy: Innovative Health Solutions (IHS), the device maker, has marketed the BRIDGE for opioid withdrawal for more than a year, even before it had clearance for that use from the Food and Drug Administration. Fact: IHS did not market the BRIDGE for opioid withdrawal prior to FDA clearance. The original 510(k)-cleared BRIDGE device was indicated for use in the acute and chronic pain population. Pain is highly prevalent in this patient population, which led some clinicians to adopt in their treatment of patients. Subsequently, IHS received clearance for a next generation product – the NSS-2 BRIDGE – with a claim that it could reduce the symptoms of opioid withdrawal. What Mr. Harper may be referring to, and what he asked IHS about previously, were conversations with policymakers in a non-promotional setting about future applications for IHS technology. In that context, as we explained to Mr. Harper, IHS has every right to discuss ongoing development and future activities, but Mr. Harper chose to ignore our input. Inaccuracy: An investigation by Side Effects Public Media and NPR reveals that researchers working with Innovative Health Solutions, maker of the BRIDGE, submitted to a medical journal a study that wasn't what it appeared to be.
    [Show full text]
  • V21 MTG 0033 List of Particip
    THE FIRST WHO INTEGRATED MEETING ON DEVELOPMENT AND CLINICAL TRIALS OF INFLUENZA VACCINES THAT INDUCE BROADLY PROTECTIVE AND LONG-LASTING IMMUNE RESPONSES Baptist University, Hong Kong 24 – 26 January 2013 LIST OF PARTICIPANTS Dr Akira Ainai, Emeritus Member, National Institute of Infectious Diseases, Tokyo, Japan Dr Christopher Ambrose, Senior Director, Medical Affairs, MedImmune, Gaithersburg, United States of America Professor Filippo Ansaldi, Health Sciences, University of Genoa and Hygiene Unit, Genoa, Italy Dr Robert L. Atmar, Associate Professor, Department of Medicine and Molecular Virology & Microbiology, Baylor College of Medicine, Houston, United States of America Dr Emma Ball, CSL Limited A.C.N., Parkville, Victoria, Australia Dr Pamuk Bilsel, FluGen Inc., Madison, United States of America Mr Albert Chan, President, Hong Kong Baptist University, Hong Kong, China Dr Paul Chan, Department of Microbiology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China Dr Marta Coehlo Nunes, Respiratory and Meningeal Pathogens Research Unit, Wits University, Johannesburg, South Africa Dr Ben Cowling, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China Dr Manon Cox, President and CEO, Protein Sciences Corporation, Meridien, United States of America Professor Rebecca Cox, Influenza Centre, The Gade Institute, University of Bergen, Bergen, 5021 Norway Dr Giuseppe Del Giudice, Global Head Translation Medicine, Novartis Vaccines and Diagnostics S.p.A, Divisione Biologici
    [Show full text]
  • Is a COVID-19 Vaccine a Good Idea for You? Will Your Life Children by Using Research Go Back to Normal? to Develop More Effective Treatments and Policies
    36 We are dedicated to improving the health and safety of adults and Is a COVID-19 Vaccine a Good Idea for You? Will Your Life children by using research Go Back to Normal? to develop more effective treatments and policies. If you are at high risk of COVID-19 because you are The Cancer Prevention older, have cancer or other serious diseases, or even if you’re at average risk, you’re probably wondering and Treatment Fund is our if you should get a vaccine as soon as possible. As major program. we write this, there is not yet a COVID-19 vaccine that is widely available. But, we have preliminary data about some of the vaccines. The goal of this article is to give you the information you need to help you make an informed decision. We will also try to answer this key question: Will the vaccines be good enough so that life goes back to normal? On October 22, the FDA held a public Advisory gotten the vaccine. That sounds very impressive. Committee meeting to discuss the scientific However, these studies must continue and it could standards needed for a COVID-19 vaccine to be be many months before the studies can conclude Our Cancer Prevention considered good enough to be sold. Food and Drug whether the vaccines prevent hospitalizations or and Treatment Fund helps Administration (FDA) approval standards are deaths of the people most at risk. And it could be higher than the standards for FDA’s “Emergency much longer before we know if people taking either adults and children reduce Use Authorization” (EUA).
    [Show full text]
  • Biennial Report 2018-19
    Cancer Prevention and Treatment Fund A voice you can trust in prevention, treatment, and policy Biennial Report 2018-2019 2 MESSAGE FROM THE PRESIDENT We persuaded Congress to proven accurate and secure for protect all Americans’ access to all patients. affordable health insurance, We trained and continue to including those with pre- work with 100 patient existing conditions such as advocates from across the cancer. country on how to make their We trained researchers and voices heard to improve journalists to better medical research on cancer communicate the results of treatments and prevention. research on which treatments We updated our free booklet are best for which patients, and for women with ductal publicized important new study carcinoma in situ (DCIS) and results. our free booklet for men about We urged the Food and Drug prostate cancer screening. We In 2018 and 2019, we helped Administration (FDA) to made both booklets widely thousands of adults and children require long-term studies of the available to patients and family get the best possible medical treat- safety and effectiveness for all members across the country. ment; we published articles and medications, implants, and Whether we were explaining well- reports that will continue to help vaccines, so that consumers physicians provide better medical established and complicated could make well-informed treatment; and we had a major im- medical research information to decisions for themselves and pact on the many invisible govern- families and health professionals, ment policies that can reduce or their children. or making sense of controversial new research on vaccines, increase our risk of cancer.
    [Show full text]